From JCO: Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

"Immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 has revolutionized the treatment of a variety of malignancies. Despite recent advances, many outstanding questions, such as the definitions of the optimal dose, schedule, combinations, and duration of therapy; the development of robust predictors of likely benefit; toxicity; and the development of better ways to manage toxicities, still need to be addressed. These questions can only be explored through prospective clinical trials and broad collaborative research."

Vi3C intends to perform research on optimal dose, schedule and duration of immunotherapy agents.

The Value in Cancer Care Consortium: Addressing Financial Toxicity

Vi3C featured at The Washington Post - by Laura McGinley

Shorter Duration of Trastuzumab May Reduce Cardiac Toxicity, Costs, at ASCO Daily News

Some patients with Stage III colon cancer need only half of long-standing course of chemotherapy, at The ASCO POST

"Taking a high-priced cancer drug with a low-fat meal can cut cost by 75%", by John Easton, Science Life News, University of Chicago News.

"Many Medicare cancer patients hit by high out-of-pocket costs", by Laurie McGinley, The Washington Post.

"The High Cost of Cancer Care May Take Physical and Emotional Toll on Patients", by Lisa Ward, The Wall Street Journal